Investor Presentaiton

1. Rs. Crs 7 Rs.Crs Revenue increased at a CAGR of 12% over FY15-19 and EBITDA increased at a CAGR of 25% over the same period Demonstrated Financial Track Record with Strong Revenue Growth and Attractive Profitability Profile Revenue from Operations¹ ● Total Revenue 5,826 5,893 5,861 7,518 9,111 6,763 Reported EBITDA² EBITDA Split¹ 732 1,291 1,370 1,558 1,775 1,438 CAGR Reported EBITDA : 25% 18 18 26 445 39 2 632 434 313 433 176 3,545 176 123 -126 182 3,328 2,356 3,144 2,882 2,576 322 1,372 892 975 1,127 977 445 Revenue CAGR: 12% FY 15 FY16 FY17 FY18 .217 Rs. Crs 5,349 4,013 4,231 2,559 2,885 3,104 FY 15 FY16 FY17 FY18 FY19 9MFY20 -1 FY19 9MFY20 Margins Pharma FY 15 FY 16 Pharma FY17 ■LSI ■DDDS FY 18 FY19 9M'FY20 LSI Reported 17.4% 30.9% 10.2% 15.0% 12.6% 21.9% 31.4% 24.3% 25.7% 26.6% 23.4% 16.8% 19.0% 20.7% 12.6% 13.3% 19.5% 21.3% PAT ■Pharma LSI DDDS EPS 25.1 36.9 41.3 36.9 40.0 Net Debt to EBITDA² 3.3 643 638 2.7 576 574 2.1 431 1.9 1.7 FY16 FY17 FY18 FY19 9M'FY20 Pharma Revenue and EBITDA includes India Branded Pharmaceuticals 2. Reported EBITDA is after Corporate Expenses 23 FY16 FY17 FY18 FY19 9M'FY20 Reported EBITDA up 14% YoY to Rs 1775 Crore. Adjusted EBITDA after one-time expenses at Rs 1,932 Crore up 17% YoY Increase in revenue and EBITDA attributable to increasing share of high margin Pharmaceuticals segment Pharma margins at 26% in FY19 and 24% in FY18 including Radiopharmacies and IBP Specialty Pharmaceuticals margin at 27.6% in FY19 as against 36.7% in FY18 CDMO margin at 31.4% in FY19 vs. 24.4% in FY18 Generics margin at 12% in FY19 vs. -6% in FY18 (including IBP) PAT at Rs 574 Crore in FY19 vs Rs 643 Crore in FY18. Normalised PAT³ at Rs 855 Crore as compared to Rs 714 Crore in FY18 Net Debt/EBITDA down to 1.9x as on 31 Mar 2019 from 3.3x as on March 31, 2016 Normalised PAT is before exceptional items of stock settlement charge of Rs 280 Cr on IFC convertible loan due to one time settlement in FY 19 and one time product development amortization charge of Rs 91 Cr in FY18 3.3x.a JUBILANT LIFESCIENCES

View entire presentation